• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Puhy Dorothy E was granted 50,913 shares, increasing direct ownership by 88% to 108,510 units (SEC Form 4)

    6/12/26 11:35:26 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    PUHY DOROTHY E

    (Last)(First)(Middle)
    1775 WEST OAK COMMONS CT NE

    (Street)
    MARIETTA GEORGIA 30062

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    MIMEDX GROUP, INC. [ MDXG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/10/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock06/10/2026A50,913(1)A$3.64108,510D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next meeting of shareholders.
    Remarks:
    /s/ William F. Hulse as attorney-in-fact Dorothy Puhy06/12/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $MDXG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDXG

    DatePrice TargetRatingAnalyst
    2/23/2026$10.00Mkt Outperform
    Citizens
    7/2/2024$11.00Overweight
    Cantor Fitzgerald
    3/7/2024$12.00Buy
    Lake Street
    10/27/2023$12.00Buy
    Craig Hallum
    10/13/2022$7.00Buy
    Mizuho
    9/14/2021$20.00 → $8.50Buy
    HC Wainwright & Co.
    7/26/2021$23.00Outperform
    Northland Capital
    More analyst ratings

    $MDXG
    SEC Filings

    View All

    MiMedx Group Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

    8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

    6/16/26 4:12:31 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by MiMedx Group Inc

    DEFA14A - MIMEDX GROUP, INC. (0001376339) (Filer)

    4/29/26 4:25:11 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

    4/29/26 4:01:07 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens initiated coverage on MiMedx Group with a new price target

    Citizens initiated coverage of MiMedx Group with a rating of Mkt Outperform and set a new price target of $10.00

    2/23/26 8:37:40 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

    Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00

    7/2/24 7:38:13 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on MiMedx Group with a new price target

    Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

    3/7/24 8:26:30 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

    Issued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow itself. One newly public name just took a concrete step toward proving it. NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — For most of medical history, the body's inability to regrow lost tissue has been treated as a fact to be managed rather than a problem to be solved. When skin, bone, or soft tissue is destroyed by injury, surgery, disease, or age, the standard of care has largely been about coverage and replacement — grafts, implants, fillers,

    6/16/26 10:30:00 AM ET
    $IART
    $MDXG
    $ORGO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus

    NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (NASDAQ:CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further into manufacturing scale-up and regulatory preparation as it works toward a planned first-quarter 2027 510(k) submission. Companies mentioned: Conexeu Scien

    6/9/26 9:54:59 AM ET
    $IART
    $MDXG
    $SNN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Specialties

    The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

    Issued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.Equity Insider Market CommentaryTAMPA, Fla., June 2, 2026 /CNW/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 wome

    6/2/26 9:00:00 AM ET
    $BVS
    $IART
    $MDXG
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MDXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bierman James L was granted 50,913 shares, increasing direct ownership by 24% to 263,684 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    6/12/26 11:39:43 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Puhy Dorothy E was granted 50,913 shares, increasing direct ownership by 88% to 108,510 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    6/12/26 11:35:26 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Newton Todd was granted 50,913 shares, increasing direct ownership by 12% to 463,684 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    6/12/26 11:32:51 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    5/5/25 10:06:51 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    11/22/23 5:01:18 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Financials

    Live finance-specific insights

    View All

    MIMEDX Announces First Quarter 2026 Operating & Financial Results

    Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2026. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "The first quarter of 2026 was adversely impacted as new Medicare reimbursement policies in the advanced wound care space went into effect at the start of the year and led to significant confusion across the industry in nearly every care setting. Additio

    4/29/26 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29

    MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, April 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13759618 A replay of the webcast will be available for approximately 30 days on the Company's

    4/22/26 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Restructuring and Cost Reduction Initiative

    MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. "On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Ricci joined the Company at a pivotal time in the organizatio

    4/16/26 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Leadership Updates

    Live Leadership Updates

    View All

    Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

    Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

    7/17/24 8:00:00 AM ET
    $MDXG
    $SAVA
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

    MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe

    6/26/24 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Appointment of Two New Independent Directors

    MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a

    3/4/24 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/12/24 4:04:33 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MiMedx Group Inc

    SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/7/24 10:25:58 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/4/24 1:30:50 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care